On September 18, 2023, Avinger disclosed that the aggregate market value of their outstanding common stock held by non-affiliates amounts to $9,846,526. This calculation is based on the 625,208 shares of outstanding common stock held by non-affiliates, with each share valued at $15.7492. Consequently, the approximate total value of Avinger’s outstanding shares of common stock held by non-affiliates is approximately $9.8 million.
Market capitalization serves as a measure of a company’s worth in the stock market. It signifies the total market value of all outstanding shares. To determine a company’s market cap, one must multiply the number of outstanding shares by the current market value of a single share. However, it is important to note that the given information about Avinger does not provide sufficient data to ascertain the company’s market capitalization. The provided information solely offers the aggregate market value of outstanding common stock held by non-affiliates, which represents only a portion of the company’s total outstanding shares.
Avinger, Inc.
AVGR
Buy
Updated on: 06/12/2023
Financial Health
Healthy
Debt to equity ratio: Strong Buy
Price to earnings ratio: Neutral
Price to book ratio: Strong Buy
DCF: Strong Buy
ROE: Strong Sell
AVGR Stock Performance Soars on September 18, 2023, Outperforming Competitors in Health Technology Sector
On September 18, 2023, Avinger, Inc. (AVGR) experienced significant stock performance, with its shares jumping from the previous close of $4.14 to an opening price of $6.30. Throughout the day, AVGR stock traded within a range of $5.70 to $8.46. The trading volume for AVGR on this day reached 1,106,940 shares, which is considerably higher than its average volume of 6,737 shares over the past three months. AVGR’s earnings growth last year was +4.63%, and this year it has skyrocketed to +98.15%. Looking ahead, analysts predict a steady earnings growth rate of +15.00% for the next five years. AVGR’s price-to-earnings (P/E) ratio is not available (NM), indicating that the company may not currently have positive earnings or is in a growth phase. However, its price-to-sales ratio of 0.82 and price-to-book ratio of 0.52 suggest that the stock may be undervalued relative to its sales and book value. On September 18, 2023, AVGR’s stock performance outperformed some of its competitors in the health technology sector. Avinger, Inc. operates in the medical specialties industry and is headquartered in Redwood City, California.
AVGR Stock Shows Strong Performance and Potential for Significant Growth in 2023
AVGR stock had a strong performance on September 18, 2023, with the potential for significant growth in the future. According to data from CNN Money, the 1 analyst offering 12-month price forecasts for Avinger Inc has a median target of $24.00. This represents a +296.69% increase from the last price of $6.05.
The high and low estimates for the stock price are also $24.00, indicating a consensus among analysts that there is a potential for substantial growth in the stock. This positive outlook is reinforced by the fact that the median estimate represents a nearly 300% increase from the current price.
Furthermore, the current consensus among 1 polled investment analysts is to buy stock in Avinger Inc. This rating has remained steady since April, indicating a consistent belief in the company’s potential. This buy rating suggests that analysts believe the stock is undervalued and has room for growth.
Investors should also be aware of the upcoming reporting date of November 8, when Avinger Inc will release its next set of financial results. This will provide further insight into the company’s performance and may impact the stock price.
Overall, based on the information provided, AVGR stock had a positive performance on September 18, 2023, with analysts predicting a significant increase in the stock price in the next 12 months. The consistent buy rating from analysts suggests a belief in the company’s potential, and investors should keep an eye on the upcoming financial results to make informed decisions.
Discussion about this post